Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LSTA
stocks logo

LSTA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
--
--
-0.650
+6.56%
--
--
-0.535
-9.32%
--
--
-0.510
-7.27%
Estimates Revision
The market is revising No Change the revenue expectations for Lisata Therapeutics, Inc. (LSTA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -6.45%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-6.45%
In Past 3 Month
Wall Street analysts forecast LSTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LSTA is 15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast LSTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LSTA is 15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.030
sliders
Low
15.00
Averages
15.00
High
15.00
Current: 2.030
sliders
Low
15.00
Averages
15.00
High
15.00
Brookline
Buy
maintain
$20 -> $32
2025-07-15
Reason
Brookline
Price Target
$20 -> $32
2025-07-15
maintain
Buy
Reason
Brookline raised the firm's price target on Lisata Therapeutics to $32 from $20 and keeps a Buy rating on the shares. The firm cites extended patent protection for the target increase after Lisata received a new patent for certepetide through March 2040.
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$15
2024-12-11
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$15
2024-12-11
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Lisata Therapeutics Inc (LSTA.O) is -1.56, compared to its 5-year average forward P/E of -1.59. For a more detailed relative valuation and DCF analysis to assess Lisata Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.59
Current PE
-1.56
Overvalued PE
-0.75
Undervalued PE
-2.43

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.77
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.78
Undervalued EV/EBITDA
-0.24

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
123.83
Current PS
0.00
Overvalued PS
585.21
Undervalued PS
-337.55
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

LSTA News & Events

Events Timeline

(ET)
2025-11-04
17:26:00
Lisata Therapeutics showcases data on iRGD cyclic peptide product candidate
select
2025-10-08 (ET)
2025-10-08
08:31:51
Lisata Therapeutics and Catalent Sign Worldwide ADC Licensing Deal
select
2025-09-29 (ET)
2025-09-29
08:06:52
Lisata Therapeutics Reveals Findings from CENDIFOX Pancreatic Cancer Study
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-06Newsfilter
Lisata Therapeutics Receives 2025 BioTech Breakthrough Award for 'Best Overall BioPharma Solution'

  • Lisata Therapeutics Award: Lisata Therapeutics has been awarded "Overall BioPharma Solution of the Year" for the second consecutive year at the BioTech Breakthrough Awards, recognizing its innovative CendR Platform® technology aimed at improving cancer treatment outcomes.

  • Clinical Trial Success: The company has reported significant clinical trial results, including a 60.8% six-month progression-free survival rate in metastatic pancreatic cancer and a 60% overall response rate in locally advanced pancreatic cancer, showcasing the effectiveness of its investigational drug, certepetide.

  • CendR Platform® Technology: Lisata's CendR Platform® enhances the delivery of anti-cancer drugs to solid tumors by activating a unique transport mechanism, which has shown to improve the efficacy of various therapies while maintaining a favorable safety profile.

  • Future Prospects: Lisata Therapeutics is focused on advancing its clinical development programs and expects to announce several milestones in the next 1.5 years, with sufficient capital to support operations into early 2027.

[object Object]
Preview
2.0
10-10TipRanks
VTI ETF Update, October 10, 2025

  • VTI Stock Performance: The Vanguard Total Stock Market ETF (VTI) has increased by 0.99% over the past week and 15.56% year-to-date, with a Moderate Buy consensus from analysts and a price target suggesting a 12.60% upside.

  • Holdings Analysis: VTI's top five holdings with the highest upside potential include FibroBiologics and Cibus, while those with the greatest downside risk include Wolfspeed and Opendoor Technologies; notably, Wolfspeed's stock surged 16.7% recently, continuing a significant rally.

[object Object]
Preview
7.5
10-09Yahoo Finance
Lisata Therapeutics Collaborates with Catalent on Antibody-Drug Conjugate Technology

  • Partnership Announcement: Lisata Therapeutics has entered a global product license agreement with Catalent, allowing Catalent to incorporate Lisata’s certepetide into antibody-drug conjugates (ADCs) using its SMARTag technology platform.

  • Significance of Collaboration: The partnership highlights the versatility of certepetide and reinforces Lisata's commitment to developing transformative therapies, as stated by Lisata’s Executive Vice President of Research and Development.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Lisata Therapeutics Inc (LSTA) stock price today?

The current price of LSTA is 2.03 USD — it has increased 5.45 % in the last trading day.

arrow icon

What is Lisata Therapeutics Inc (LSTA)'s business?

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.

arrow icon

What is the price predicton of LSTA Stock?

Wall Street analysts forecast LSTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LSTA is 15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Lisata Therapeutics Inc (LSTA)'s revenue for the last quarter?

Lisata Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Lisata Therapeutics Inc (LSTA)'s earnings per share (EPS) for the last quarter?

Lisata Therapeutics Inc. EPS for the last quarter amounts to -0.49 USD, decreased -16.95 % YoY.

arrow icon

What changes have occurred in the market's expectations for Lisata Therapeutics Inc (LSTA)'s fundamentals?

The market is revising No Change the revenue expectations for Lisata Therapeutics, Inc. (LSTA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -6.45%.
arrow icon

How many employees does Lisata Therapeutics Inc (LSTA). have?

Lisata Therapeutics Inc (LSTA) has 26 emplpoyees as of December 05 2025.

arrow icon

What is Lisata Therapeutics Inc (LSTA) market cap?

Today LSTA has the market capitalization of 17.91M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free